Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
October 02 2023 - 6:00AM
Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today
announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to
its Board of Directors. Dr. Kirk is internationally recognized for
his work in organ transplantation, with a specialized focus on
kidney transplants and transplant immunology. He is currently
Chairman of the Department of Surgery and Surgeon-in-Chief at Duke
University School of Medicine. He is also the David C. Sabiston,
Jr. Professor of Surgery, a Professor of Integrative Immunobiology,
and a Professor of Pediatrics at Duke.
“We are pleased to have Dr. Kirk join our Board of Directors at
a pivotal time at the company following initiation of our Phase 2
BESTOW trial evaluating tegoprubart for the prevention of organ
rejection in patients receiving a kidney transplant,” said
David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. “Dr.
Kirk’s renowned expertise in the field of organ transplantation,
including kidney transplantation, will be incredibly valuable as we
advance tegoprubart in clinical development on our mission to
fulfill an urgent unmet need for the thousands of patients in need
of an organ transplant. I look forward to working closely
together.”
“Organ transplantation remains an area of significant unmet need
– a need that is often overlooked or underrecognized – and my
decades of research have been driven by my desire to improve
immunosuppression regimens for transplant patients. Transplant
recipients deserve new treatment options with better efficacy and
fewer side-effects to help protect their transplanted organs,” said
Dr. Kirk. “I am proud to join the Eledon team on their mission to
bring patients a novel treatment option that has the potential to
transform immunosuppression and improve the lives of patients.”
Dr. Kirk served as the inaugural Chief of the Transplantation
Branch for the National Institute of Diabetes and Digestive and
Kidney Diseases and has been a principal investigator for multiple
clinical trials, including the first-in-human experience with novel
immunosuppressive agents. Dr. Kirk has helped pioneer the use of
co-stimulation pathway blockade to prevent organ rejection in
transplant patients. He has a special interest in immune management
of transplant recipients, including therapies that influence T cell
co-stimulation pathways and adjuvant therapies that facilitate
co-stimulation blockade to prevent the rejection of transplanted
organs without undue suppression of protective immunity. His
research is directed toward understanding transplant rejection and
translating this understanding into improved therapies for
transplant recipients. He has co-authored hundreds of peer-reviewed
journal publications.
Dr. Kirk is a member of the Duke Transplant Center and is a core
faculty member of the Duke Innovation & Entrepreneurship
program. He also previously served as Editor-in-Chief for the
American Journal of Transplantation. Dr. Kirk earned an M.D. from
Duke University School of Medicine, a Ph.D. from Duke University
and a B.S. from Old Dominion University.
About Eledon Pharmaceuticals and tegoprubart (formerly
AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company
with immunology expertise that is developing therapies to protect
and prevent rejection of transplanted organs, as well as to treat
amyotrophic lateral sclerosis (ALS). The Company’s lead compound in
development is tegoprubart, an anti-CD40L antibody with high
affinity for CD40 Ligand (also called “CD154”), a well-validated
biological target with broad therapeutic potential. Eledon is
headquartered in Irvine, California. For more information, please
visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn;
Twitter
Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. Any statements about
planned clinical trials and the Company’s other future
expectations, plans and prospects, as well as other statements
containing the words “believes,” “anticipates,” “plans,” “expects,”
“estimates,” “intends,” “predicts,” “projects,” “targets,” “looks
forward,” “could,” “may,” and similar expressions, constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are inherently uncertain and are subject to numerous
risks and uncertainties, including: risks relating to the safety
and efficacy of our drug candidates; risks relating to clinical
development timelines, including interactions with regulators and
clinical sides, as well as patient enrollment; risks relating to
costs of clinical trials and the sufficiency of the company’s
capital resources to fund planned clinical trials; and risks
associated with the impact of the ongoing coronavirus pandemic.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various factors. These
risks and uncertainties, as well as other risks and uncertainties
that could cause the company’s actual results to differ
significantly from the forward-looking statements contained herein,
are discussed in our quarterly 10-Q, annual 10-K, and other filings
with the U.S. Securities and Exchange Commission, which can be
found at www.sec.gov. Any forward-looking statements contained in
this press release speak only as of the date hereof and not of any
future date, and the company expressly disclaims any intent to
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Contact:
Stephen JasperGilmartin Group(858) 525
2047stephen@gilmartinir.com
Media Contact:
Jenna UrbanBerry & Company Public Relations(212) 253
8881jurban@berrypr.com
Source: Eledon Pharmaceuticals
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From May 2024 to Jun 2024
Eledon Pharmaceuticals (NASDAQ:ELDN)
Historical Stock Chart
From Jun 2023 to Jun 2024